AstraZeneca’s (AZN) “Buy” Rating Reiterated at Jefferies Financial Group

AstraZeneca (LON:AZN)‘s stock had its “buy” rating reissued by Jefferies Financial Group in a report released on Tuesday, Digital Look reports. They currently have a £175 target price on the biopharmaceutical company’s stock. Jefferies Financial Group‘s target price points to a potential upside of 34.82% from the stock’s current price.

Other equities research analysts have also issued reports about the stock. Deutsche Bank Aktiengesellschaft reiterated a “hold” rating and set a £117 target price on shares of AstraZeneca in a research report on Tuesday, September 29th. Citigroup increased their price target on shares of AstraZeneca from £175 to £178 and gave the stock a “buy” rating in a report on Tuesday, July 28th. Royal Bank Of Canada restated an “outperform” rating and set a £145 price objective on shares of AstraZeneca in a research report on Tuesday, September 8th. Finally, Berenberg Bank restated a “buy” rating and set a £175 price objective on shares of AstraZeneca in a research report on Wednesday, October 7th. Six analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of £153.57.

AstraZeneca Stock Up 2.9%

AZN stock opened at £129.80 on Tuesday. The company has a current ratio of 0.89, a quick ratio of 0.59 and a debt-to-equity ratio of 64.10. The company’s 50 day moving average is £121.60 and its 200 day moving average is £130.60. The stock has a market cap of £201.31 billion, a price-to-earnings ratio of 19.43, a price-to-earnings-growth ratio of 0.86 and a beta of 0.20. AstraZeneca has a 1-year low of £114.04 and a 1-year high of £157.32.

Insiders Place Their Bets

In related news, insider Michel Demare acquired 2,500 shares of the stock in a transaction on Monday, September 14th. The stock was purchased at an average price of £121.21 per share, for a total transaction of £303,025. Insiders own 0.15% of the company’s stock.

AstraZeneca Company Profile

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.
Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.